Studies have shown the feasibility of detecting mutation status by blood and urine circulating tumor DNA (ctDNA)in non-small cell lung cancer (NSCLC) patients. However, no prospective has been conducted for usage of ctDNA in postoperative surveillance of NSCLC patients.
We plan to compare tumor makers and radiographic approaches with blood and urine ctDNA in surveillance to assess the lead time of postoperative tumor relapse in stage ⅢA NSCLC patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18 to 80 years
Undergo radical surgery（R0 resection）
Histologically confirmed diagnosis of stage ⅢA non-small cell lung cancer
Positive Driver mutation(EGFR、PTEN、PIK3CA、BRAF、K-RAS、Her2) in tumor tissue
Blood or urine circulating tumor detect the driver mutation detected in tumor tissue
Patients must have given written informed consent
You may not be if
Unable to comply with the study procedure
Malignant tumor history within the past 5 years
Patients who received any treatment prior to resection
R1 or R2 resection
Coexisting small cell lung cancer
Received target drug therapy after surgery
Unqualified blood or urine samples
Clareo Health | Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
